Funds
Torax Medical receives a $30 million investment
Name Torax medical
Target The proceeds will be used to expand commercialization efforts for the company’s unique family of sphincter augmentation products
Investors Piper Jaffray Merchant Banking, Sanderling Ventures, Thomas Mcnerney & Partners, Accuitive Medical Ventures, Kaiser Permanente and Mayo Medical Ventures
FUND Torax medical secures $30m financing to commercialize pioneering treatment for reflux disease.
INVESTOR The $30 million Series D round of financing was led by Piper Jaffray Merchant Banking. Sanderling Ventures, Thomas, McNerney & Partners, Accuitive Medical Ventures, Kaiser Permanente and Mayo Medical Ventures also participated.
TARGET The proceeds will be used to expand commercialization efforts for the company’s unique family of sphincter augmentation products. The company’s lead product, the LINX® Reflux Management System, is a surgical treatment of Gastroesophageal reflux disease (GERD). LINX was approved by the US Food and Drug Administration (FDA)
in March following a unanimous recommendation by an FDA advisory review panel.
PEOPLE Torax Medical, Inc. is a privately held medical device company headquartered in St. Paul, Minnesota that develops and markets products designed to treat chronic diseases related to defective sphincter muscles. The company’s technology platform, Magnetic Sphincter Augmentation (MSA), employs a small implant comprised of interlinked titanium beads with magnetic cores. The magnetic attraction between the beads augments the existing sphincter’s barrier function to prevent reflux or incontinence. The devices are implanted with standard minimally invasive laparoscopic or surgical procedures. The LINX Reflux Management System for the treatment of GERD is marketed in both the USA and in Europe and the FENIX™ Continence Restoration System for the treatment of Fecal incontinence (FI) is marketed in Europe.
Foundation Medicine receives a $42.5 million investment
FUND Foundation Medicine Announces $42.5 Million Series B Financing
INVESTOR In this round, public crossover funds Deerfield Management Company, L.P., Casdin Capital, Redmile Group and strategic investors Roche Venture Fund and WuXi Corporate Venture Fund joined founding investor Third Rock Ventures and current venture capital backers Google Ventures and Kleiner Perkins Caufield & Byers. One undisclosed fund and one undisclosed strategic investor also joined the round. Foundation Medicine’s board of directors remains unchanged.
TARGET The proceeds from the financing will help Foundation Medicine expand commercial operations, scale laboratory capabilities and develop additional genomic profiling and information services. FoundationOne™ is a genomic assay for all solid tumors that identifies oncogenic alterations in the tumor and provides a concise report to help physicians match patients with the targeted drugs or clinical trials that may be best suited for their unique cancer. Launched in June 2012, FoundationOne has already been ordered by more than 400 physicians from 16 countries.
Name Foundation Medicine
Target To expand commercial operations, scale laboratory capabilities and develop additional genomic profiling and information services.
Investors Third Rock Ventures, Google Ventures, Kleiner Perkins Caufield & Byers, Deerfield Management Company, L.P., Casdin Capital, Redmile Group, Roche Venture Fund and WuXi Coorporate Venture Fund
Virtual Instruments Raises $27.5 Million in Series D Funding
Name Virtual Instruments
Target invest in product development and expand its market presence.
Investors Next World Capital, General Catalyst Partners & Lightspeed Venture Partners
FUND Virtual Instruments, the leader in Infrastructure Performance Management (IPM) for physical, virtual and cloud computing environments, today announced $27.5 million in Series D funding.
INVESTOR The funding round was co-led by Next World Capital and General Catalyst Partners with continued participation from existing investor Lightspeed Venture Partners.
TARGET Virtual Instruments will use the funding to invest in product development and expand its market presence.
PEOPLE Virtual Instruments is a leader in Infrastructure Performance Management for physical, virtual and cloud computing environments. The award-winning VirtualWisdom® platform provides visibility into real-time performance and health of the entire open systems stack along with metrics that assess utilization. Virtual Instruments improves the performance and availability of mission-critical applications while lowering the cost of the supporting infrastructure. Forbes Magazine recognized the company as #6 on its 2011 list of America's Most Promising Companies. Virtual Instruments investors include General Catalyst Partners, Lightspeed Venture Partners, Next World Capital and Riverwood Capital. The company was founded in June 2008 via a spin-out from Finisar Corp.; it has headquarters in San Jose, Calif., and can be found online at
http://www.virtualinstruments.com.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112